Background/Aims: In postnatal life, polymorphisms in the promoter region of IGFBP3 were associated with insulin-like growth factor binding protein (IGFBP)-3 plasma levels. Whether these associations exist in utero has not been studied yet. Polymorphisms in the IGF1 promoter (polymorphic CA-repeat) and the insulin gene variable number tandem repeats locus (INS VNTR) are further polymorphisms of interest, because associations with birth weight have been reported. We aimed to investigate associations between polymorphisms in the promoter regions of IGF1 (wild type 192 bp), IGFBP3 (rs2854744; rs13241830), and INS VNTR (rs689) with cord plasma levels of IGF-I, IGF-II, and IGFBP-3. Methods: We measured IGF-I, IGF-II, and IGFBP-3 concentrations in cord blood from 677 neonates and genotyped the selected polymorphisms. Results: Carriers of the minor allele of both polymorphisms in the IGFBP3 gene had, on average, 4–5% lower IGFBP-3 levels per copy of the respective minor allele (p = 0.002 and p = 0.028) when compared to wild type carriers. The IGF1 promoter and the INS VNTR polymorphisms were not associated with IGF-I, IGF-II, or IGFBP-3 levels. Conclusions: Our data show associations of cord plasma IGFBP-3 levels and the IGFBP3 gene variants but not of IGF1 promoter and INS VNTR polymorphisms with IGF-I, IGF-II, or IGFBP-3 levels in utero.

Keywords:
Polymorphism, IGF-I, IGF-II, IGFBP-3, Umbilical cord plasma
1.
Murphy VE, Smith R, Giles WB, Clifton VL: Endocrine regulation of human fetal growth: the role of the mother, placenta, and fetus. Endocr Rev 2006;27:141–169.
2.
Juul A, Dalgaard P, Blum WF, Bang P, Hall K, Michaelsen KF, Muller J, Skakkebaek NE: Serum levels of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in healthy infants, children, and adolescents: the relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, age, sex, body mass index, and pubertal maturation. J Clin Endocrinol Metab 1995;80:2534–2542.
3.
Godfrey KM, Hales CN, Osmond C, Barker DJ, Taylor KP: Relation of cord plasma concentrations of proinsulin, 32–33 split proinsulin, insulin and C-peptide to placental weight and the baby’s size and proportions at birth. Early Hum Dev 1996;46:129–140.
4.
Paquette J, Bessette B, Ledru E, Deal C: Identification of upstream stimulatory factor binding sites in the human IGFBP3 promoter and potential implication of adjacent single-nucleotide polymorphisms and responsiveness to insulin. Endocrinology 2007;148:6007–6018.
5.
Al-Zahrani A, Sandhu MS, Luben RN, Thompson D, Baynes C, Pooley KA, Luccarini C, Munday H, Perkins B, Smith P, Pharoah PD, Wareham NJ, Easton DF, Ponder BA, Dunning AM: IGF1 and IGFBP3 tagging polymorphisms are associated with circulating levels of IGF1, IGFBP3 and risk of breast cancer. Hum Mol Genet 2006;15:1–10.
6.
Cheng I, DeLellis Henderson K, Haiman CA, Kolonel LN, Henderson BE, Freedman ML, Le Marchand L: Genetic determinants of circulating insulin-like growth factor (IGF)-I, IGF binding protein (BP)-1, and IGFBP-3 levels in a multiethnic population. J Clin Endocrinol Metab 2007;92:3660–3666.
7.
Jernstrom H, Deal C, Wilkin F, Chu W, Tao Y, Majeed N, Hudson T, Narod SA, Pollak M: Genetic and nongenetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in healthy premenopausal women. Cancer Epidemiol Biomarkers Prev 2001;10:377–384.
8.
Deal C, Ma J, Wilkin F, Paquette J, Rozen F, Ge B, Hudson T, Stampfer M, Pollak M: Novel promoter polymorphism in insulin-like growth factor-binding protein-3: correlation with serum levels and interaction with known regulators. J Clin Endocrinol Metab 2001;86:1274–1280.
9.
Canzian F, McKay JD, Cleveland RJ, Dossus L, Biessy C, Rinaldi S, Landi S, Boillot C, Monnier S, Chajes V, Clavel-Chapelon F, Tehard B, Chang-Claude J, Linseisen J, Lahmann PH, Pischon T, Trichopoulos D, Trichopoulou A, Zilis D, Palli D, Tumino R, Vineis P, Berrino F, Bueno-de-Mesquita HB, van Gils CH, Peeters PH, Pera G, Ardanaz E, Chirlaque MD, Quiros JR, Larranaga N, Martinez-Garcia C, Allen NE, Key TJ, Bingham SA, Khaw KT, Slimani N, Norat T, Riboli E, Kaaks R: Polymorphisms of genes coding for insulin-like growth factor 1 and its major binding proteins, circulating levels of IGF-I and IGFBP-3 and breast cancer risk: results from the EPIC study. Br J Cancer 2006;94:299–307.
10.
Schumacher FR, Cheng I, Freedman ML, Mucci L, Allen NE, Pollak MN, Hayes RB, Stram DO, Canzian F, Henderson BE, Hunter DJ, Virtamo J, Manjer J, Gaziano JM, Kolonel LN, Tjonneland A, Albanes D, Calle EE, Giovannucci E, Crawford ED, Haiman CA, Kraft P, Willett WC, Thun MJ, Le Marchand L, Kaaks R, Feigelson HS, Bueno-de-Mesquita HB, Palli D, Riboli E, Lund E, Amiano P, Andriole G, Dunning AM, Trichopoulos D, Stampfer MJ, Key TJ, Ma J: A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians. Hum Mol Genet 2010;19:3089–3101.
11.
Costalonga EF, Antonini SR, Guerra-Junior G, Mendonca BB, Arnhold IJP, Jorge AAL: The –202 A allele of insulin-like growth factor binding protein-3 (IGFBP3) promoter polymorphism is associated with higher IGFBP-3 serum levels and better growth response to growth hormone treatment in patients with severe growth hormone deficiency. J Clin Endocrinol Metab 2009;94:588–595.
12.
van der Kaay DC, Hendriks AE, Ester WA, Leunissen RW, Willemsen RH, de Kort SW, Paquette JR, Hokken-Koelega AC, Deal CL: Genetic and epigenetic variability in the gene for IGFBP-3 (IGFBP3): correlation with serum IGFBP-3 levels and growth in short children born small for gestational age. Growth Horm IGF Res 2009;19:198–205.
13.
Dunger OK, Huxtable SJ, Sherriff A, Woods KA, Ahmed ML, Golding J, Pembrey ME, Ring S, Bennett ST, Todd JA: Association of the INS VNTR with size at birth. Nat Genet 1998;19:98–100.
14.
Vaessen N, Janssen JA, Heutink P, Hofman A, Lamberts SW, Oostra BA, Pols HA, van Duijn CM: Association between genetic variation in the gene for insulin-like growth factor-I and low birthweight. Lancet 2002;359:1036–1037.
15.
Frayling TM, Hattersley AT, McCarthy A, Holly J, Mitchell SM, Gloyn AL, Owen K, Davies D, Smith GD, Ben-Shlomo Y: A putative functional polymorphism in the IGF-I gene: association studies with type 2 diabetes, adult height, glucose tolerance, and fetal growth in UK populations. Diabetes 2002;51:2313–2316.
16.
Mitchell SM, Hattersley AT, Knight B, Turner T, Metcalf BS, Voss LD, Davies D, McCarthy A, Wilkin TJ, Smith GD, Ben-Shlomo Y, Frayling TM: Lack of support for a role of the insulin gene variable number of tandem repeats minisatellite (INS-VNTR) locus in fetal growth or type 2 diabetes-related intermediate traits in United Kingdom populations. J Clin Endocrinol Metab 2004;89:310–317.
17.
Mook-Kanamori DO, Miranda Geelhoed JJ, Steegers EA, Witteman JC, Hofman A, Moll HA, van Duijn CM, Hokken-Koelega AC, Jaddoe VW: Insulin gene variable number of tandem repeats is not associated with weight from fetal life until infancy: the Generation R Study. Eur J Endocrinol 2007;157:741–748.
18.
Maas JA, Mook-Kanamori DO, Ay L, Steegers EA, van Duijn CM, Hofman A, Hokken-Koelega AC, Jaddoe VW: Insulin VNTR and IGF-1 promoter region polymorphisms are not associated with body composition in early childhood: the generation R study. Horm Res Paediatr 2010;73:120–127.
19.
Vafiadis P, Bennett ST, Colle E, Grabs R, Goodyer CG, Polychronakos C: Imprinted and genotype-specific expression of genes at the IDDM2 locus in pancreas and leucocytes. J Autoimmun 1996;9:397–403.
20.
Pugliese A, Zeller M, Fernandez A Jr, Zalcberg LJ, Bartlett RJ, Ricordi C, Pietropaolo M, Eisenbarth GS, Bennett ST, Patel DD: The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes. Nat Genet 1997;15:293–297.
21.
Paquette J, Giannoukakis N, Polychronakos C, Vafiadis P, Deal C: The INS 5′ variable number of tandem repeats is associated with IGF2 expression in humans. J Biol Chem 1998;273:14158–14164.
22.
Gluckman PD, Hanson MA: Living with the past: evolution, development, and patterns of disease. Science 2004;305:1733–1736.
23.
McMillen IC, Robinson JS: Developmental origins of the metabolic syndrome: prediction, plasticity, and programming. Physiol Rev 2005;85:571–633.
24.
Harder T, Rodekamp E, Schellong K, Dudenhausen JW, Plagemann A: Birth weight and subsequent risk of type 2 diabetes: a meta-analysis. Am J Epidemiol 2007;165:849–857.
25.
LeRoith D, Yakar S: Mechanisms of disease: metabolic effects of growth hormone and insulin-like growth factor 1. Nat Clin Pract Endocrinol Metab 2007;3:302–310.
26.
Clemmons DR: Involvement of insulin-like growth factor-I in the control of glucose homeostasis. Curr Opin Pharmacol 2006;6:620–625.
27.
Hunt KJ, Lukanova A, Rinaldi S, Lundin E, Norat T, Palmqvist R, Stattin P, Riboli E, Hallmans G, Kaaks R: A potential inverse association between insulin-like growth factor I and hypertension in a cross-sectional study. Ann Epidemiol 2006;16:563–571.
28.
Ezzat VA, Duncan ER, Wheatcroft SB, Kearney MT: The role of IGF-I and its binding proteins in the development of type 2 diabetes and cardiovascular disease. Diabetes Obes Metab 2008;10:198–211.
29.
Perticone F, Sciacqua A, Perticone M, Laino I, Miceli S, Care I, Galiano Leone G, Andreozzi F, Maio R, Sesti G: Low plasma insulin-like growth factor-1 levels are associated with impaired endothelium-dependent vasodilatation in a cohort of untreated hypertensive Caucasian subjects. J Clin Endocrinol Metab 2008;93:2806–2810.
30.
Voigt M, Schneider KT, Jahrig K: Analysis of a 1992 birth sample in Germany. 1: New percentile values of the body weight of newborn infants (in German). Geburtshilfe Frauenheilkd 1996;56:550–558.
31.
Mook-Kanamori DO, Steegers EA, Uitterlinden AG, Moll HA, van Duijn CM, Hofman A, Jaddoe VW: Breast-feeding modifies the association of PPARgamma2 polymorphism Pro12Ala with growth in early life: the Generation R Study. Diabetes 2009;58:992–998.
32.
Adkins RM, Fain JN, Krushkal J, Klauser CK, Magann EF, Morrison JC: Association between paternally inherited haplotypes upstream of the insulin gene and umbilical cord IGF-II levels. Pediatr Res 2007;62:451–455.
33.
Bennett ST, Todd JA: Human type 1 diabetes and the insulin gene: principles of mapping polygenes. Annu Rev Genet 1996;30:343–370.
34.
Landmann E, Geller F, Schilling J, Rudloff S, Föller-Gaudier E, Gortner L: A polymorphism in the insulin-like growth factor I promoter gene but not in the insulin gene variable number of tandem repeat locus is associated with accelerated weight gain in infancy. Pediatrics 2006;118:2374–2379.
35.
Blum WF, Ranke MB: Use of insulin-like growth factor-binding protein 3 for the evaluation of growth disorders. Horm Res 1990;3:31–37.
36.
Blum WF, Schweizer R: Insulin-like growth factors and their binding proteins; in Ranke MB (ed): Diagnostics of Endocrine Function in Children and Adolescents. Basel, Karger, 2003, pp 166–199.
37.
Baglietto L, English DR, Hopper JL, Morris HA, Tilley WD, Giles GG: Circulating insulin-like growth factor-I and binding protein-3 and the risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2007;16:763–768.
38.
Severi G, Morris HA, MacInnis RJ, English DR, Tilley WD, Hopper JL, Boyle P, Giles GG: Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006;15:1137–1141.
39.
Chan SS, Twigg SM, Firth SM, Baxter RC: Insulin-like growth factor binding protein-3 leads to insulin resistance in adipocytes. J Clin Endocrinol Metab 2005;90:6588–6595.
40.
Kim HS, Ali O, Shim M, Lee KW, Vuguin P, Muzumdar R, Barzilai N, Cohen P: Insulin-like growth factor binding protein-3 induces insulin resistance in adipocytes in vitro and in rats in vivo. Pediatr Res 2007;61:159–164.
41.
Ong KK, Petry CJ, Barratt BJ, Ring S, Cordell HJ, Wingate DL, Pembrey ME, Todd JA, Dunger DB: Maternal-fetal interactions and birth order influence insulin variable number of tandem repeats allele class associations with head size at birth and childhood weight gain. Diabetes 2004;53:1128–1133.
42.
Bennett AJ, Sovio U, Ruokonen A, Martikainen H, Pouta A, Taponen S, Hartikainen AL, King VJ, Elliott P, Jarvelin MR, McCarthy MI: Variation at the insulin gene VNTR (variable number tandem repeat) polymorphism and early growth: studies in a large Finnish birth cohort. Diabetes 2004;53:2126–2131.
43.
Levitt NS, Lambert EV, Woods D, Hales CN, Andrew R, Seckl JR: Impaired glucose tolerance and elevated blood pressure in low birth weight, nonobese, young South African adults: early programming of cortisol axis. J Clin Endocrinol Metab 2000;85:4611–4618.
44.
Kingdom JC, McQueen J, Connell JM, Whittle MJ: Fetal angiotensin II levels and vascular (type I) angiotensin receptors in pregnancies complicated by intrauterine growth retardation. Br J Obstet Gynaecol 1993;100:476–482.
45.
Jaquet D, Deghmoun S, Chevenne D, Collin D, Czernichow P, Levy-Marchal C: Dynamic change in adiposity from fetal to postnatal life is involved in the metabolic syndrome associated with reduced fetal growth. Diabetologia 2005;48:849–855.
46.
Fagerberg B, Bondjers L, Nilsson P: Low birth weight in combination with catch-up growth predicts the occurrence of the metabolic syndrome in men at late middle age: the Atherosclerosis and Insulin Resistance study. J Intern Med 2004;256:254–259.
47.
Hemachandra AH, Howards PP, Furth SL, Klebanoff MA: Birth weight, postnatal growth, and risk for high blood pressure at 7 years of age: results from the Collaborative Perinatal Project. Pediatrics 2007;119:1264–1270.
48.
Rosen CJ, Kurland ES, Vereault D, Adler RA, Rackoff PJ, Craig WY, Witte S, Rogers J, Bilezikian JP: Association between serum insulin growth factor-I (IGF-I) and a simple sequence repeat in IGF-I gene: implications for genetic studies of bone mineral density. J Clin Endocrinol Metab 1998;83:2286–2290.
49.
Vaessen N, Heutink P, Janssen JA, Witteman JC, Testers L, Hofman A, Lamberts SW, Oostra BA, Pols HA, van Duijn CM: A polymorphism in the gene for IGF-I: functional properties and risk for type 2 diabetes and myocardial infarction. Diabetes 2001;50:637–642.
50.
Kinoshita Y, Kizaki Z, Ishihara Y, Nakajima H, Adachi S, Kosaka K, Kinugasa A, Sugimoto T: The relationship in Japanese infants between a genetic polymorphism in the promoter region of the insulin-like growth factor I gene and the plasma level. Neonatology 2007;92:116–119.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.